Podcasts

East Coast Symposium presenter Anelia Shaheed, JD, Esq, a partner at the law offices of Julie W. Allison, discusses best practices for avoiding reimbursement claim denials.

Lisa Richardson, CEO and co-founder of Beyond Healthcare, discusses the importance of connection and community, both in caring for clients and their families, as well as for building a healthy workplace for staff.

Youturn Health CEO Hamilton Baiden and Senior Director of Marketing Celia Hamilton discuss the rebranding process for the former Heritage CARES, and share best practices for other organizations considering a similar move.

Nicole Bradberry, co-founder and chief innovation officer for Arizona-based MIND 24-7, discusses the company’s tiered approach to emergency and crisis mental and psychiatric health and substance use disorder care.

Paul Thielking, MD, chief scientific officer for Novamind, discusses the company's current clinical trials, how psychedelics are garnering interest from physicians, and issues that will have to be navigated for psychedelics treatments in...

Mindset Pharma CEO James Lanthier discusses his organization’s development of next-generation psychedelic drugs and their potential applications for treating various mental health conditions.

ACHC's Denise Hobson discusses accreditation pain points for behavioral healthcare organizations and shares tips for using the commission's reports to help improve performance.

Brian Mears, Alleviant Health Centers founder, president and CEO, discusses best practices for behavioral healthcare providers who are interested in adding a ketamine-assisted treatment option to their service offerings.

Sierra Tucson Group CEO Valerie Kading, DNP, MBA, MSN, PMHNP-BC, who presented at the Treatment Center Investment & Valuation Retreat on Sunday, discusses best practices for how treatment centers can develop a “client-obsessed culture" that...

Numinus Wellness CEO and founder Payton Nyquvest discusses the emergence of psychedelics, how psychedelic-assisted psychotherapy integrates with existing treatment modalities, as well as investors' interest and payers' views on psychedelics.